trial

A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

NCTId NCT00827918
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 216 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2010-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
216 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-03
Primary completion
2010-04
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
MK-8998Olanzapine

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

0 total

Linked catalysts

1
A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Particip — primary completion2010-04

Facts & assertions

4 sourced
Enrollment
216
Phase
PHASE2
Primary Completion Date
2010-04
Status
COMPLETED
relationships
The graph out of here
drug
MK-8998
drug
Olanzapine
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication